https://www.am-pharma.com/jama-publishes-phase-ii-recap-data-for-sepsis-associated-acute-kidney-injury/ 2019-06-24T13:30:27+00:00 https://www.am-pharma.com/am-pharma-announces-phase-ii-study-results-of-recap-in-sepsis-associated-acute-kidney-injury/ 2019-07-10T16:12:37+00:00 https://www.am-pharma.com/am-pharma-expands-its-senior-team-in-preparation-for-a-pivotal-phase-iii-trial-of-recap-in-acute-kidney-injury/ 2019-10-01T09:46:42+00:00 https://www.am-pharma.com/am-pharma-adds-regulatory-business-development-and-legal-expertise-to-leadership-team/ 2020-06-29T10:02:38+00:00 https://www.am-pharma.com/__trashed/ 2020-07-01T09:00:58+00:00 https://www.am-pharma.com/am-pharma-appoints-chief-medical-officer-and-vp-manufacturing-to-support-global-pivotal-trial-in-sepsis-associated-acute-kidney-injury/ 2020-10-20T09:01:52+00:00 https://www.am-pharma.com/am-pharma-announces-enrollment-of-the-first-patient-in-revival-phase-iii-pivotal-trial-in-patients-with-sepsis-associated-acute-kidney-injury/ 2020-11-12T10:00:10+00:00 https://www.am-pharma.com/improvement-of-the-skeletal-and-dental-hypophosphatasia-phenotype-in-alpl%e2%88%92-%e2%88%92-mice-by-administration-of-soluble-non-targeted-chimeric-alkaline-phosphatase/ 2021-01-07T12:22:16+00:00 https://www.am-pharma.com/am-pharma-announces-enrollment-and-financing-of-covid-19-cohort-in-phase-iii-revival-trial/ 2021-03-02T08:43:18+00:00 https://www.am-pharma.com/am-pharma-increases-funding-to-e163m-for-phase-iii-trial-of-recap-in-sa-aki/ 2021-04-28T13:28:53+00:00 https://www.am-pharma.com/am-pharma-raises-e116m-133m-to-conduct-pivotal-phase-iii-trial-of-recap-in-acute-kidney-injury/ 2021-04-28T13:32:29+00:00 https://www.am-pharma.com/am-pharma-enrolls-first-patient-in-japan-for-ongoing-phase-iii-sa-aki-pivotal-revival-trial/ 2021-07-01T11:45:28+00:00 https://www.am-pharma.com/am-pharma-appoints-mark-altmeyer-as-chairman-of-its-supervisory-board/ 2021-07-09T07:40:25+00:00 https://www.am-pharma.com/am-pharma-appoints-martijn-negen-as-vp-commercial-strategy/ 2021-07-09T07:47:24+00:00 https://www.am-pharma.com/am-pharma-and-kyowa-kirin-sign-exclusive-license-agreement-for-commercialization-of-ilofotase-alfa-in-japan/ 2021-09-08T07:13:47+00:00 https://www.am-pharma.com/am-pharma-appoints-lars-boesgaard-as-chief-financial-officer-and-establishes-u-s-affiliate-am-pharma-inc/ 2021-09-16T07:10:03+00:00 https://www.am-pharma.com/am-pharma-appoints-alexander-bastian-as-vice-president-value-market-access/ 2022-01-04T20:50:31+00:00 https://www.am-pharma.com/am-pharma-to-participate-in-upcoming-investor-conferences/ 2022-01-10T19:39:01+00:00 https://www.am-pharma.com/am-pharma-and-leading-experts-publish-report-on-state-of-the-art-clinical-trials-in-acute-kidney-injury/ 2022-01-26T10:03:45+00:00 https://www.am-pharma.com/am-pharma-to-participate-in-upcoming-investor-and-scientific-conferences/ 2022-03-03T11:31:39+00:00 https://www.am-pharma.com/am-pharma-announces-two-presentations-at-the-27th-international-conference-on-advances-in-critical-care-nephrology/ 2022-03-07T13:05:14+00:00 https://www.am-pharma.com/am-pharma-to-participate-in-svb-leerink-biopharma-private-company-connect/ 2022-03-22T13:41:24+00:00 https://www.am-pharma.com/2596-2/ 2022-04-25T12:10:05+00:00 https://www.am-pharma.com/am-pharma-to-participate-in-upcoming-jefferies-healthcare-conference/ 2022-06-06T14:52:13+00:00 https://www.am-pharma.com/am-pharma-announces-publication-of-in-vivo-acute-kidney-injury-study-demonstrating-ilofotase-alfas-dual-protective-mechanism/ 2022-07-05T14:58:04+00:00 https://www.am-pharma.com/am-pharma-provides-business-update-and-outcome-of-pre-planned-interim-futility-analysis-of-phase-3-revival-study/ 2022-10-20T09:09:48+00:00 https://www.am-pharma.com/am-pharma-announces-updated-clinical-development-strategy/ 2023-09-26T09:00:16+00:00 https://www.am-pharma.com/am-pharma-announces-positive-clinical-data-from-phase-1b-study-evaluating-ilofotase-alfa-in-hypophosphatasia-patients/ 2023-10-11T09:55:39+00:00 https://www.am-pharma.com/am-pharma-initiates-phase-2-trial-of-ilofotase-alfa-for-cardiac-surgery-associated-renal-damage/ 2024-01-16T10:22:12+00:00 https://www.am-pharma.com/am-pharma-completes-enrollment-in-phase-2-study-of-ilofotase-alfa-for-prevention-of-cardiac-surgery-associated-renal-damage/ 2025-10-02T09:00:02+00:00 https://www.am-pharma.com/a-randomized-phase-1b-trial-evaluating-the-pharmacodynamics-of-ilofotase-alfa-in-adults-with-hypophosphatasia/ 2026-01-06T10:55:22+00:00 https://www.am-pharma.com/a-molecular-based-estimation-of-the-prevalence-of-hypophosphatasia-in-the-european-population/ 2026-01-06T10:57:32+00:00 https://www.am-pharma.com/impact-of-muscular-symptoms-and-or-pain-on-disease-characteristics-disability-and-quality-of-life-in-adult-patients-with-hypophosphatasia-a-cross-sectional-analysis-from-the-global-hpp-registry/ 2026-01-06T10:59:58+00:00 https://www.am-pharma.com/improved-vo%e2%82%82max-muscle-function-and-endurance-in-adult-hpp-pako-mice-treated-with-ilofotase-alfa/ 2026-01-06T11:02:34+00:00